Sana adds hypoimmunogenic stem cell tech from Harvard to its tool kit

Building out its portfolio of cell and gene therapy tools, Sana licensed technology from Harvard University comprising methods to create stem cells that avoid triggering immune rejection when transplanted.

The hypoimmunogenic stem cells are derived from human pluripotent stem cells that have been genetically modified to reduce the activity of genes whose proteins can provoke a transplant recipient’s immune system, and to increase the activity of genes that produce tolerogenic factors. The stem cells can also be differentiated into any cell type...